Clinical Trials
Sep 22, 2026 · 1 min read · 79,768 views
Merck plans a sac-TMT combo trial with Keytruda as patent cliff looms
D
Daniel Park
Editorial · Sep 22, 2026
Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda. The company plans to conduct a trial
← Previous
Roivant's road to a potential blockbuster begins with FDA approval for Lisraya
Next →
Ziopharm rebrands to Alaunos, closes Boston office with new CEO at the reins
